A.S. Gardberg

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Andrew T. Bender, A.S. Gardberg, Albertina Pereira et al. · Molecular Pharmacology · 2017 · 176 citations

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 136 citations · Full text

Novel Therapy, Medicine, Tyrosine Kinase +14

Increasing the structural coverage of tuberculosis drug targets

Loren Baugh, Isabelle Phan, Darren W. Begley et al. · Tuberculosis · 2014 · 128 citations · Full text

Pulmonary Tuberculosis, Drug Target, Structural Coverage +8

Combining Functional and Structural Genomics to Sample the Essential Burkholderia Structome

Loren Baugh, Larry A. Gallagher, Rapatbhorn Patrapuvich et al. · PLoS ONE · 2013 · 128 citations · Full text

Molecular basis for passive immunotherapy of Alzheimer's disease

A.S. Gardberg, Lezlee Dice, Susan Ou et al. · Proceedings of the National Academy of Sciences · 2007 · 108 citations · Full text

Peptide Engineering, Immunology, Molecular Biology +17